

Changes to Specification

On page 1, after the title and before the first paragraph, please insert the following paragraph:

This application is a divisional of Serial No. 09/171,945, filed October 29, 1998, ^{now} *US PATENT* 6,277,599

Added Abstract of the Disclosure

ABSTRACT OF THE DISCLOSURE

An anti-CEA monoclonal antibody, designated 806.077, of murine origin is useful for the diagnosis and therapy of cancer. The antibody complementarity determining regions have the following sequences: heavy chain CDR1 DBYMH CDR2 WIDPENGDT EYAPKFRG, CDR3 LIYAGYLAMD Y; and light chain CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. The antibody optionally is humanized and can be in the form of a conjugate with either an enzyme, such as carboxypeptidase, or a co-stimulatory molecule such as the extracellular domain of human B7.1.